Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Xilio Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- 0 vs. Q1 2025
- Shares held
- 23.8M
- +1.27M (+5.6%) vs. Q1 2025
- Total value
- $16.2M
- −$139.5K (−0.9%) vs. Q1 2025
- New holders
- 5
- 4 more added
- Sold out
- 5
- 11 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Private Wealth Management Group, LLC | 310 | $211 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 331 | $225 | 0.00% | +41+14.1% | Added |
| Key Financial Inc | 830 | $564 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,037 | $1.39K | 0.00% | −72,663−97.3% | Reduced |
| Federation des caisses Desjardins du Quebec | 3,300 | $2.24K | 0.00% | 00.0% | Unchanged |
| Investors Asset Management of Georgia Inc | 10,000 | $6.80K | 0.00% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $6.80K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $6.99K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 15,412 | $10.5K | 0.00% | +15,412 | New |
| Raymond James Financial Inc | 18,761 | $12.8K | 0.00% | −15,200−44.8% | Reduced |
| Aptus Capital Advisors, LLC | 25,000 | $17.0K | 0.00% | −21,000−45.7% | Reduced |
| Mariner, LLC | 25,000 | $17.0K | 0.00% | 00.0% | Unchanged |
| SevenBridge Financial Group, LLC | 25,000 | $17.5K | 0.00% | −21,000−45.7% | Reduced |
| LPL Financial LLC | 31,000 | $21.1K | 0.00% | +31,000 | New |
| XTX Topco Ltd | 34,721 | $23.6K | 0.00% | +34,721 | New |
| State Street Corp | 43,390 | $29.5K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 56,081 | $38.1K | 0.00% | −15,000−21.1% | Reduced |
| Northern Trust Corp | 66,609 | $45.3K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 78,032 | $53.1K | 0.00% | −6,036−7.2% | Reduced |
| Avantax Planning Partners, Inc. | 142,338 | $96.8K | 0.00% | −8,061−5.4% | Reduced |
| Renaissance Technologies LLC | 164,200 | $111.6K | 0.00% | −13,500−7.6% | Reduced |
| Balyasny Asset Management LLC | 198,859 | $135.2K | 0.00% | −55,487−21.8% | Reduced |
| Squarepoint Ops LLC | 235,456 | $160.1K | 0.00% | +235,456 | New |
| UBS Group AG | 239,969 | $163.2K | 0.00% | +76,868+47.1% | Added |
| Trustees of Columbia University in the City of New York | 249,635 | $169.8K | 0.02% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 369,660 | $251.4K | 0.00% | −9,356−2.5% | Reduced |
| FMR LLC | 511,820 | $348.0K | 0.00% | −372,215−42.1% | Reduced |
| AJU IB Investment Co., Ltd. | 667,742 | $454.0K | 0.49% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,151,023 | $782.7K | 0.00% | +15,307+1.3% | Added |
| Ghisallo Capital Management LLC | 1,333,000 | $906.3K | 0.02% | +1,333,000 | New |
| Morgan Stanley | 1,444,326 | $982.0K | 0.00% | +288,488+25.0% | Added |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.00M | 5.13% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,483,758 | $1.01M | 0.47% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $3.10M | 0.39% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 9,105,451 | $6.19M | 0.48% | 00.0% | Unchanged |
| Millennium Management LLC | 0 | $0 | 0.00% | −51,110−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −42,546−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −62−100.0% | Sold out |